Clinical Trial Update: Ilaris (Canakinumab) in the Schnitzler Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial of canakinumab (Ilaris) in Schnitzler Syndrome has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schnitzler Syndrome

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Schnitzler Syndrome | Phase 2 | Status: COMPLETED